Tandem Diabetes Care Inc. has announced a new partnership with Abbott to enhance diabetes management technology. The collaboration integrates Tandem's t:slim X2™ insulin pump, equipped with Control-IQ+ automated insulin delivery technology, with Abbott's FreeStyle Libre® 3 Plus continuous glucose monitoring sensor. This integration aims to offer personalized solutions for people living with diabetes by allowing the insulin pump to receive automatic glucose readings every minute from the sensor. The partnership is set to expand the availability of this integrated system in the United States starting the second half of 2025, with plans to extend access to international markets later this year.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。